Publications

2014 - current

Ali T, Klein AN, McDonald K, Johansson L, Mukherjee PG, Hallbeck M, Doh-ura K, Schatzl HM, Gilch S. Cellulose ether treatment inhibits amyloid beta aggregation, neuroinflammation and cognitive deficits in transgenic mouse model of Alzheimer’s disease. J. Neuroinflammation. 2023 20(1):177.

Ali T, Klein AN, Vu A, Arifin MI, Hannaoui S, Gilch S. Peptide aptamer targeting Aβ–PrP–Fyn axis reduces Alzheimer’s disease pathologies in 5XFAD transgenic mouse model. Cell Mol Life Sci. 2023 80(6):139.

Gilch S. Schatzl HM. New developments in prion disease research. Cell Tissue Res. 2023 392(1):1-5.

Arifin MI, Kaczmarczyk L, Zeng D, Hannaoui S, Lee C, Chang SC, Mitchell G, McKenzie D, Beekes M, Jackson W, Gilch S. Heterozygosity for cervid S138N polymorphism results in subclinical CWD in gene-targeted mice and progressive inhibition of prion conversion. PNAS. 2023 120 (15) e2221060120

Cherry P, Lu L, Shim SY, Ebacher V, Tahir W, Schatzl HM, Hannaoui S, Gilch S. Loss of small GTPase Rab7 activation in prion infection negatively affects a feedback loop regulating neuronal cholesterol metabolism. J Biol Chem. 2023 299(2):102883.

Ness A, Zeng D, Kuznetsova A, Otero A, Kim C, Saboraki K, Lingle S, Pybus M, Aiken J, Gilch S, McKenzie D. Chronic wasting disease prions in mule deer interdigital glands. PLoS One. 2022 17(10):e0275375.

Hannaoui, S, Zemlyankina I, Chang SC, Arifin MI, Béringue V, McKenzie D, Schatzl HM, Gilch S. Transmission of cervid prions to humanized mice demonstrates the zoonotic potential of CWD. Acta Neuropathol. 2022 144(4):767-784

Cashion J, Zhang W, Ali T, Gilch S. Cholesterol and its reciprocal association with prion infection. Cell Tissue Res. 2022. 

Gilch S. Chronic wasting disease — A prion disease through a One Health lens. Can Vet J. 2022 63(4): 431–433

Thapa S, Marrero Winkens C, Tahir W, Arifin MI, Gilch S, Schatzl HM. Gene-Edited Cell Models to Study Chronic Wasting Disease. Viruses. 2022 Mar 15;14(3):609.

Linsenmeier L, Mohammadi B, Shafiq M, Frontzek K, Bär J, Shrivastava AN, Damme M, Song F, Schwarz A, Da Vela S, Massignan T, Jung S, Correia A, Schmitz M, Puig B, Hornemann S, Zerr I, Tatzelt J, Biasini E, Saftig P, Schweizer M, Svergun D, Amin L, Mazzola F, Varani L, Thapa S, Gilch S, Schätzl H, Harris DA, Triller A, Mikhaylova M, Aguzzi A, Altmeppen HC, Glatzel M. Ligands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies. Sci Adv. 2021 ;7(48):eabj1826. 

Hannaoui S, Triscott E, Duque Velásquez C, Chang SC, Arifin MI, Zemlyankina I, Tang X, Bollinger T, Wille H, McKenzie D, Gilch S. New and distinct chronic wasting disease strains associated with cervid polymorphism at codon 116 of the Prnp gene. Plos Pathog. 2021 17(7): e1009795.

Teruya K, Oguma A, Arai K, Nishizawa K, Iwabuchi S, Watanabe-Matsui M, Sakasegawa Y, Schätzl H, Gilch S, Doh-Ura K. Polymorphisms in glia maturation factor β gene are markers of cellulose ether effectiveness in prion-infected mice. Biochem Biophys Res Commun. 2021 Jun 30;560:105-111.

Ali T, Hannaoui S, Nemani S, Tahir W, Zemlyankina I, Cherry P, Shim SY, Sim V, Schaetzl HM, Gilch S. Oral administration of repurposed drug targeting Cyp46A1 increases survival times of prion infected mice. Acta Neuropathol Commun. 2021 9(1):58

Arifin MI, Hannaoui S, Chang SC, Thapa S, Schatzl HM, Gilch S. Cervid Prion Protein Polymorphisms: Role in Chronic Wasting Disease Pathogenesis. Int J Mol Sci. 2021 22(5):2271

Cherry P, Gilch S. The Role of Vesicle Trafficking Defects in the Pathogenesis of Prion and Prion-Like Disorders. Int J Mol Sci. 2020 21(19):7016

Arifin MI, Staskevicius A, Shim SY, Huang YH, Fenton H, McLoughlin PD, Mitchell G, Cullingham CI, Gilch S. Large-scale prion protein genotyping in Canadian caribou populations and potential impact on chronic wasting disease susceptibility. Mol Ecol. 2020 29(20):3830-3840

Hannaoui S, Arifin MI, Chang SC, Yu J, Gopalakrishnan P, Doh-Ura K, Schatzl HM, Gilch S. Cellulose ether treatment in vivo generates chronic wasting disease prions with reduced protease resistance and delayed disease progression. J Neurochem. 2020 152(6):727-740

Haley NJ, Donner R, Henderson DM, Tennant J, Hoover EA, Manca M, Caughey B, Kondru N, Manne S, Kanthasamay A, Hannaoui S, Chang SC, Gilch S, Smiley S, Mitchell G, Lehmkuhl AD, Thomsen BV. Cross-validation of the RT-QuIC assay for the antemortem detection of chronic wasting disease in elk. Prion. 2020 14(1):47-55

Abdulrahman BA, Tahir W, Doh-Ura K, Gilch S, Schatzl HM. Combining autophagy stimulators and cellulose ethers for therapy against prion disease. Prion. 2019 13(1):185-196

Walia R, Ho CC, Lee C, Gilch S, Schatzl HM. Gene-edited murine cell lines for propagation of chronic wasting disease prions Sci Rep. 2019 9(1):11151

Abdelaziz DH, Abdulrahman BA, Gilch S, Schatzl HM. Autophagy pathways in the treatment of prion diseases. Curr Opin Pharmacol. 2019 44:46-52.

Nishizawa K, Teruya K, Oguma A, Sakasegawa Y, Schätzl H, Gilch S, Doh-Ura K. Preparation and Characterization of Cellulose Ether Liposomes for the Inhibition of Prion Formation in Prion-Infected Cells. J Pharm Sci. 2019 108(8):2814-2820

Castle AR, Daude N, Gilch S, Westaway D. Application of high-throughput, capillary-based Western analysis to modulated cleavage of the cellular prion protein. J Biol Chem. 2019 294(8):2642-2650

Klein AN, Corda E, Gilch S. Peptide aptamer-mediated modulation of prion protein α-cleavage as treatment strategy for prion and other neurodegenerative diseases. Neural Regen Res. 2018 13(12):2108-2110

Haley NJ, Richt JA, Davenport KA, Henderson DM, Hoover EA, Manca M, Caughey B, Marthaler D, Bartz J, Gilch S. Design, implementation, and interpretation of amplification studies for prion detection. Prion. 2018 12(2):73-82

Corda E, Du X, Shim SY, Klein AN, Siltberg-Liberles J, Gilch S. Interaction of peptide aptamers with prion protein central domain promotes α-cleavage of PrPC. Molecular Neurobiology. 2018. 55(10):7758-7774

Abdulrahman BA, Abdelaziz D, Thapa S, Lu L, Jain S, Gilch S, Proniuk S, Zukiwski A, Schatzl HM. The celecoxib derivatives AR-12 and AR-14 induce autophagy and clear prion-infected cells from prions. Sci Rep. 2017 7:17565.

Hannaoui S, Schatzl H, Gilch S. Chronic wasting disease: Emerging prions and their potential risk. PLoS Pathog. 2017 13(11): e1006619.

Hannaoui S, Amidian S, Cheng YC, Duque Velásquez C, Dorosh L, Law S, Telling G, Stepanova M, McKenzie D, Wille H, Gilch S. Destabilizing polymorphism in cervid prion protein hydrophobic core determines prion conformation and conversion efficiency. PLOS Pathogens. 2017 13(8): e1006553.

Cheng YC, Hannaoui S, John TR, Dudas S, Czub S, Gilch S. Real-time Quaking-induced Conversion Assay for Detection of CWD Prions in Fecal Material.  J Vis Exp. 2017 Sep 29;(127).

Cheng YC, Musiani M, Cavedon M, Gilch S. High prevalence of prion protein genotype associated with resistance to chronic wasting disease in one Alberta woodland caribou population. Prion. 2017 28:1-7.

Cheng YC, Hannaoui S, John TR, Dudas S, Czub S, Gilch S. Early and Non-Invasive Detection of Chronic Wasting Disease Prions in Elk Feces by Real-Time Quaking Induced Conversion. PLoS One. 2016 11:e0166187.

Shim SY, Karri S, Law S, Schatzl HM, Gilch S. Prion infection impairs lysosomal degradation capacity by interfering with rab7 membrane attachment in neuronal cells. Sci Rep. 2016 6: 21658.

Hannaoui S, Shim SY, Cheng YC, Corda E, Gilch S. Cholesterol Balance in Prion Diseases and Alzheimer's Disease. Viruses. 2014 6:4505-4535. 

Salta E, Kanata E, Ouzounis CA, Gilch S, Schätzl H, Sklaviadis T. Assessing proteinase k resistance of fish prion proteins in a scrapie-infected mouse neuroblastoma cell line. Viruses. 2014 6:4398-421.

2011 - 2013

John TR, Schatzl HM, Gilch S. Early detection of chronic wasting disease prions in urine or pre-symptomatic deer by real-time quaking-induced conversion assay. Prion. 2013 7:253-8.

Montag J, Brameier M, Schmaedicke AC, Gilch S, Schatzl HM, Motzkus D. A genome-wide survey for prion-regulated miRNAs associated with cholesterol homeostasis. BMC Genomics. 2012 13:486.

Lisa S, Domingo B, Martínez J, Gilch S, Llopis JF, Schätzl HM, Gasset M. Failure of prion protein oxidative folding guides the formation of toxic transmembrane forms. J Biol Chem. 2012 287:36693-701.

Schneider M, Ackermann K, Stuart M, Wex C, Protzer U, Schätzl HM, Gilch S. SARS-CoV replication is severely impaired by MG132 due to proteasome-independent inhibition of m-calpain. J Virol. 2012 86:10112-22.

Nunziante M, Ackermann K, Dietrich K, Wolf H, Gädtke L, Gilch S, Vorberg I, Groschup M, Schätzl HM. Proteasomal dysfunction and endoplasmic reticulum stress enhance trafficking of prion protein aggregates through the secretory pathway and increase accumulation of pathologic prion protein. J Biol Chem. 2011 286:33942-53.

Gilch S, Chitoor N, Taguchi Y, Stuart M, Jewell JE, Schätzl HM. Chronic wasting disease.Top Curr Chem. 2011 305:51-77.

2005 - 2010

Roffé M, Beraldo FH, Bester R, Nunziante M, Bach C, Mancini G, Gilch S, Vorberg I, Castilho BA, Martins VR, Hajj GN. Prion protein interaction with stress-inducible protein 1 enhances neuronal protein synthesis via mTOR. Proc Natl Acad Sci U S A. 2010 107:13147-52.

Gilch S, Bach C, Lutzny G, Vorberg I, Schätzl HM. Inhibition of cholesterol recycling impairs cellular PrP(Sc) propagation. Cell Mol Life Sci. 2009 66:3979-91.

Bach C, Gilch S, Rost R, Greenwood AD, Horsch M, Hajj GN, Brodesser S, Facius A, Schädler S, Sandhoff K, Beckers J, Leib-Mösch C, Schätzl HM, Vorberg I. Prion-induced activation of cholesterogenic gene expression by Srebp2 in neuronal cells. J Biol Chem. 2009 284:31260-9.

Gilch S, Schätzl HM. Aptamers against prion proteins and prions. Cell Mol Life Sci. 2009 66:2445-55.

Aguib Y*, Heiseke A*, Gilch S, Riemer C, Baier M, Schätzl HM, Ertmer A. Autophagy induction by trehalose counteracts cellular prion infection. Autophagy. 2009 5:361-9. *contributed equally

Krammer C, Vorberg I, Schätzl HM, Gilch S. Therapy in prion diseases: from molecular    and cellular biology to therapeutic targets. Infect Disord Drug Targets. 2009 9:3-14.

Gilch S, Krammer C, Schätzl HM. Targeting prion proteins in neurodegenerative disease. Expert Opin Biol Ther. 2008 8:923-40.

Aguib Y, Gilch S, Krammer C, Ertmer A, Groschup MH, Schätzl HM. Neuroendocrine cultured cells counteract persistent prion infection by down-regulation of PrPc. Mol Cell Neurosci. 2008 38:98-109.

Diemer C, Schneider M, Seebach J, Quaas J, Frösner G, Schätzl HM, Gilch S. Cell type specific cleavage of nucleocapsid protein by effector caspases during SARS coronavirus infection. J Mol Biol. 2008 376:23-34.

Gilch S, Schmitz F, Aguib Y, Kehler C, Bülow S, Bauer S, Kremmer E, Schätzl HM. CpG and LPS can interfere negatively with prion clearance in macrophage and microglial cells. FEBS J. 2007 274:5834-44.

Yun SW, Ertmer A, Flechsig E, Gilch S, Riederer P, Gerlach M, Schätzl HM, Klein MA. The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery. J Neurovirol. 2007 13:328-37.

Lefebvre-Roque M, Kremmer E, Gilch S, Zou WQ, Féraudet C, Gilles CM, Salès N, Grassi J, Gambetti P, Baron T, Schätzl H, Lasmézas CI. Toxic effects of intracerebral PrP antibody administration during the course of BSE infection in mice. Prion. 2007 1:198-206.

Gilch S, Kehler C, Schätzl HM. Peptide aptamers expressed in the secretory pathway    interfere with cellular PrPSc formation. J Mol Biol. 2007 371:362-73. 

Gilch S, Nunziante M, Ertmer A, Schätzl HM. Strategies for eliminating PrP(c) as substrate for prion conversion and for enhancing PrP(Sc) degradation. Vet Microbiol. 2007 123:377-86.

Ertmer A, Huber V, Gilch S, Yoshimori T, Erfle V, Duyster J, Elsässer HP, Schätzl HM. The anticancer drug imatinib induces cellular autophagy. Leukemia. 2007 21:936-42.

Handisurya A, Gilch S, Winter D, Shafti-Keramat S, Maurer D, Schätzl HM, Kirnbauer R.Vaccination with prion peptide-displaying papilloma virus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells. FEBS J. 2007 274:1747-58.

Oboznaya MB, Gilch S, Titova MA, Koroev DO, Volkova TD, Volpina OM, Schätzl HM. Antibodies to a nonconjugated prion protein peptide 95-123 interfere with PrP(Sc) propagation in prion-infected cells. Cell Mol Neurobiol. 2007 27:271-84.

Stengel A, Bach C, Vorberg I, Frank O, Gilch S, Lutzny G, Seifarth W, Erfle V, Maas E, Schätzl H, Leib-Mösch C, Greenwood AD. Prion infection influences murine endogenous retrovirus expression in neuronal cells. Biochem Biophys Res Commun. 2006 343:825-31.

Gilch S, Kehler C, Schätzl HM. The prion protein requires cholesterol for cell surface localization. Mol Cell Neurosci. 2006 31:346-53.

2000 - 2004

Ertmer A, Gilch S, Yun SW, Flechsig E, Klebl B, Stein-Gerlach M, Klein MA, Schätzl HM. The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells. J Biol Chem. 2004 279:41918-27.

Gilch S, Nunziante M, Ertmer A, Wopfner F, Laszlo L, Schätzl HM. Recognition of lumenal prion protein aggregates by post-ER quality control mechanisms is mediated by the preoctarepeat region of PrP. Traffic. 2004 5:300-13.

Nunziante M, Gilch S, Schätzl HM. Prion diseases: from molecular biology to intervention strategies. Chembiochem. 2003 4:1268-84.

Gilch S, Schätzl HM. Promising developments bringing prion diseases closer to therapy and prophylaxis. Trends Mol Med. 2003 9:367-9.

Gilch S, Wopfner F, Renner-Müller I, Kremmer E, Bauer C, Wolf E, Brem G, Groschup MH, Schätzl HM. Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J Biol Chem. 2003 278:18524-31.

Nunziante M, Gilch S, Schätzl HM. Essential role of the prion protein N terminus in subcellular trafficking and half-life of cellular prion protein. J Biol Chem. 2003 278:3726-34.

Proske D*, Gilch S*, Wopfner F, Schätzl HM, Winnacker EL, Famulok M. Prion-protein-specific aptamer reduces PrPSc formation. Chembiochem. 2002 3:717-25. *contributed equally

Gilch S, Winklhofer KF, Groschup MH, Nunziante M, Lucassen R, Spielhaupter C, Muranyi W, Riesner D, Tatzelt J, Schätzl HM. Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease. EMBO J. 2001  20:3957-66.

Gilch S, Spielhaupter C, Schätzl HM. Shortest known prion protein allele in highly BSE-susceptible lemurs. Biol Chem. 2000 381:521-3.

1993 - 1999

Wopfner F, Weidenhöfer G, Schneider R, von Brunn A, Gilch S, Schwarz TF, Werner T, Schätzl HM. Analysis of 27 mammalian and 9 avian PrPs reveals high conservation of flexible regions of the prion protein. J Mol Biol. 1999 289:1163-78.

Schwarz TF, Gilch S, Schätzl HM. A recombinant Toscana virus nucleoprotein in a diagnostic immunoblot test system. Res Virol. 1998 149:413-8.

Schätzl HM, Wopfner F, Gilch S, von Brunn A, Jäger G. Is codon 129 of prion protein polymorphic in human beings but not in animals? Lancet. 1997 349:1603-4.

Schwarz TF, Jäger G, Gilch S. Comparison of seven commercial tests for the detection of parvovirus B19-specific IgM. Zentralbl Bakteriol. 1997 285:525-30.

Schwarz TF, Nsanze H, Longson M, Nitschko H, Gilch S, Shurie H, Ameen A, Zahir AR, Acharya UG, Jager G Polymerase chain reaction for diagnosis and identification of distinct variants of Crimean-Congo hemorrhagic fever virus in the United Arab Emirates. Am J Trop Med Hyg. 1996 55:190-6.

Schwarz TF, Gilch S, Pauli C, Jäger G. Immunoblot detection of antibodies to Toscana virus. J Med Virol. 1996 49:83-6.

Schwarz TF, Jäger G, Gilch S, Pauli C, Eisenhut M, Nitschko H, Hegenscheid B. Travel-related vector-borne virus infections in Germany. Arch Virol Suppl. 1996 11:57-65.

Schwarz TF, Jäger G, Gilch S. Imported dengue virus infections in German tourists. Zentralbl Bakteriol. 1995 282:533-6.

Schwarz TF, Jäger G, Gilch S, Nitschko H. Nested RT-PCR for detection of sandfly fever virus, serotype Toscana, in clinical specimens, with confirmation by nucleotide sequence analysis. Res Virol. 1995 146:355-62.

Schwarz TF, Gilch S, Jäger G. Aseptic meningitis caused by sandfly fever virus, serotype Toscana. Clin Infect Dis. 1995 21:669-71.

Schwarz TF, Jäger G, Gilch S, Pauli C. Serosurvey and laboratory diagnosis of imported sandfly fever virus, serotype Toscana, infection in Germany. Epidemiol Infect. 1995 114:501-10.

Schwarz TF, Dobler G, Gilch S, Jäger G. Hepatitis C and arboviral antibodies in the island populations of Mauritius and Rodrigues. J Med Virol. 1994 44:379-83.

Schwarz TF, Gilch S, Jäger G. Travel-related Toscana virus infection. Lancet. 1993 342:803-4.

Diemer C, Schneider M, Schätzl HM, Gilch, S. Host cell-specific modulation of cell death by structural and accessory proteins. in Molecular Biology of the SARS-Coronavirus (2010) ed. Sunil K. Lal, pp 231-247

Nunziante M, Gilch S,  Schätzl, HM. Insights into the cellular trafficking of prion proteins. in: Neurodegeneration and prion diseases (2005) ed. D. Brown, pp 379-406.